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Type 2 diabetes is commonly accompanied by a low level of high density lipoprotein cholesterol (HDL-C) that contributes to the 
increased cardiovascular risk associated with this condition. Given that HDLs have the ability to improve increase the uptake of 
glucose by skeletal muscle and to stimulate the secretion of insulin from pancreatic beta cells the possibility arises that a low HDL 
concentration in type 2 diabetes may also contribute to a worsening of diabetic control. Thus, there is a double case for raising 
the level of HDL–C in patients with type 2 diabetes: to reduce cardiovascular risk and to improve glycemic control. Approaches 
to raising HDL–C include lifestyle factors such as weight reduction, increased physical activity and stopping smoking. Of currently 
available drugs, the most effective is niacin. Newer formulations of niacin are reasonably well tolerated and have the ability to in-
crease HDL–C by up to 30%. The effect of niacin on cardiovascular events in type 2 diabetes is currently being tested in a large-
scale clinical outcome trial.
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INTRODUCTION
Many patients with type 2 diabetes have a low concentration 
of high density lipoprotein cholesterol (HDL–C). The fact that 
a low level of HDL-C is a predictor of cardiovascular disease, it 
follows that a low level of HDL–C in patients with type 2 diabe-
tes may contribute to the increased cardiovascular risk associ-
ated with this condition. The precise cause of the low HDL–C 
in type 2 diabetes is not known but may be the consequence of 
insulin resistance, augmented very low density lipoprotein 
production and increased activities of cholesteryl ester trans-
fer protein (CETP) and endothelial lipase. Recent studies 
showing that HDLs have the ability to improve increase the 
uptake of glucose by skeletal muscle [1] and to stimulate the 
secretion of insulin from pancreatic beta cells [2] raise the 
possibility that the low HDL concentration in type 2 diabetes 
may also contribute to a worsening of diabetic control or, in-
deed, to the progression of prediabetes to the full diabetic 
state. Therefore, a low concentration of HDLs may not only be 
a consequence of the diabetes and a contributor to the increased 
cardiovascular risk in diabetics but may also result in a wors-
ening of glycemic control in people with type 2 diabetes. 
POSSIBLE MECHANISMS RESPONSIBLE FOR 
A LOW HDL-C IN DIABETES
The typical dyslipidemia in type 2 diabetes includes an elevat-
ed level of plasma triglyceride, a low level of HDL–C and a low 
density lipoprotein (LDL) fraction that is characterized by small 
dense particles [3]. The low level of HDL–C in these patients is 
associated with the presence of HDL particles are also smaller 
and denser than normal. Since it is known that the particle size 
of HDLs correlates inversely with the concentration of plasma 
triglyceride, the low level of HDL–C associated with diabetes 
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may be secondary to an elevated level of plasma triglyceride. 
This inverse relationship between the concentrations of HDL–
C and plasma triglyceride is the consequence of an increased 
rate of HDL catabolism that may be secondary to triglyceride 
enrichment of HDL particles in a mechanism dependent on 
the activities of CETP and hepatic lipase [4] as outlined in Fig. 1. 
CARDIO-PROTECTIVE PROPERTIES OF HDLS
HDLs have a number of properties with the potential to protect 
against cardiovascular disease (Table 1) [5]. The best known of 
these relates to the ability of HDLs to promote the efflux of 
cholesterol from macrophages in the artery wall. However, 
HDLs have several additional properties with the potential to 
protect against the consequences of atherosclerotic vascular 
disease. These include anti-oxidant, anti-thrombotic and anti-
inflammatory effects and the ability to promote both the func-
tion and repair of the endothelium. Some of the potentially 
protective functions of HDLs may be compromised in patients 
with diabetes. There is also evidence that HDLs have the capac-
ity to improve diabetic control and possibly to protect against 
the development of type 2 diabetes [2]. 
HDL FUNCTION IS COMPROMISED IN DIABETES
Apolipoprotein (apo) A-I (the major HDL apolipoprotein) 
may become glycated in people with diabetes. Such glycation 
has been reported to impair both the ability of HDLs to pro-
mote cholesterol efflux from macrophages [6] and their ability 
to inhibit vascular inflammation [7]. This finding is of poten-
tial patho-physiological significance given that subjects with 
type 2 diabetes, especially those with micro- and macro-vas-
cular complications, tend to be in a pro-inflammatory state. 
This highlights the importance of maintaining good glycemic 
control in people with diabetes and raises the possibility that 
therapeutic intervention with cross-link breakers, which re-
portedly prevent protein modifications, may have the poten-
tial to decrease the risk of the microvascular, and possibly the 
macrovascular complications that accompany diabetes. It is of 
interest to note that the endothelial vasoprotective effects of 
HDLs are impaired in patients with type 2 diabetes [8]. How-
ever, when diabetic subjects are treated with niacin, the endo-
thelial protective properties of HDLs are restored [8]. 
EFFECTS OF HDLS ON GLUCOSE HOMEOSTASIS
There is a growing body of experimental evidence that HDLs 
have beneficial effects on glucose homeostasis by both increas-
ing pancreatic beta cell function and by enhancing plasma 
glucose disposal. 
Table 1. Potential protective properties of high density lipo-
proteins
• Promote cholesterol efflux from macrophages in artery wall
• Anti-oxidant properties
• Anti-thrombotic properties
• Inhibit vascular inflammation
• Improve endothelial function
• Promote endothelial repair
• Improve diabetic control
HDL
TGR-LP
TG
CE
TG
CE
TG
CE
TG
CE
TG FFA
HL
CETP + FFA
HDL
(Depleted of CE, enriched with TG)
Small, dense HDL
(Depleted of CE, TG and apoA-I)
apoA-I
Lipid-poor
apoA-I
Fig. 1. Cholesteryl ester transfer protein (CETP) promotes the 
transfer of cholesteryl esters (CE) from high density lipopro-
teins (HDLs) to triglyceride-rich lipoproteins (TGR-LPs) in 
exchange for triglyceride (TG) to generate HDLs that are de-
pleted of CE and enriched in TG. This TG enrichment pro-
vides HDLs with the preferred substrate for hepatic lipase. 
Subsequent hydrolysis of the newly acquired HDL TG by he-
patic lipase leads to a reduction in volume of the particle core, 
a consequent decrease in particle size and a dissociation of lip-
id-free/lipid-poor apolipoprotein (apo) A-I from the HDL 
particle surface. The dissociation of lipid-poor apoA-I from 
HDLs provides an explanation for why the concentrations of 
both HDL–C and apoA-I tend to be low in states of hypertri-
glyceridemia such as occur in type 2 diabetes. Given that free 
fatty acids (FFAs) enhance the CETP-mediated remodelling of 
HDLs, such remodelling (and the associated low levels of 
HDL–C and apoA-I) may be exaggerated in patients with type 
2 diabetes, a condition in which the concentration of FFAs in 
plasma is elevated as a consequence of the associated insulin 
resistance.103
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HDLs and pancreatic beta cell function
The ATP binding cassette transporter A1 (ABCA1) promotes 
efflux of cholesterol from cells to lipid-free/lipid-poor apoA-I 
in the extracellular space. It has been suggested that ABCA1 
deletion results in cholesterol accumulation in the cell mem-
brane of beta cells, with a subsequent inhibition of the exocy-
tosis of insulin from secretory granules, and inhibition of in-
sulin secretion [9]. It has also been reported that HDLs have 
beneficial effects on beta cells by inhibiting apoptosis [10]. 
And more recently, it has been shown in studies conducted in 
vitro using both Min6 cells and primary islets that HDLs iso-
lated from human plasma and also the major HDL proteins, 
apoA-I and apoA-II, increase insulin synthesis and secretion 
up to 5-fold [2]. 
HDL and muscle glucose uptake
The observation that HDLs increase cellular glucose uptake in 
cultures of primary human skeletal muscle cells isolated from 
patients with type 2 diabetes mellitus [1] adds further support 
to the view that HDLs have the capacity to improve diabetic 
control (and possibly delay the development of new onset dia-
betes) by several mechanisms. 
STRATEGIES FOR RAISING HDL–C IN 
PATIENTS WITH TYPE 2 DIABETES
Lifestyle
Weight reduction 
Most overweight people have a low level of HDL–C. Further-
more, weight reduction is usually accompanied by an increase 
in the HDL–C level, although to be effective, the weight loss 
needs to be substantial and sustained. The mechanism under-
lying a relationship between body weight and HDL-C concen-
tration is uncertain. However, the fact that most patients with 
type 2 diabetes are overweight provides a strong basis for rec-
ommending weight reduction as a strategy to raise the level of 
HDL–C in such patients.
Physical activity 
High levels of aerobic activity are associated with high levels of 
HDL–C. Furthermore, increasing the level of physical activity 
in people with low levels of HDL–C, especially in those who 
are overweight, increases the HDL–C concentration. An exer-
cise-induced increase in the level of HDL–C may be second-
ary to an increased activity of lipoprotein lipase and the conse-
quent reduction in concentration of plasma triglyceride. It has 
been argued that the single most important preventable cause 
of low HDL–C in the modern world is a low level of physical 
activity.
  A recent meta-analysis has confirmed the benefit of regular 
aerobic exercise on raising HDL–C levels and provided some 
insights into how much exercise is required [11]. The analysis 
included 25 randomized controlled studies that were designed 
to evaluate the effect of exercise training on HDL–C levels. 
Overall, the mean exercise-induced increase in HDL–C was 
2.53 mg/dL (P<0.001). Importantly, an increase in HDL–C 
concentration was apparent only in people who expended at 
least 900 kcal or exercised for at least 120 minutes each week. 
In these people, every 10 minutes prolongation of exercise per 
session was associated with a 1.4 mg/dL increase in HDL–C. 
In further analyses it was found that the increase in HDL–C 
was greatest in people whose body mass index was <28 kg/m
2.
  These findings re-enforce recommendations for increasing 
levels of activity as a cardio-protective strategy in people with 
type 2 diabetes.
Alcohol consumption
Alcohol consumption increases the level of HDL–C, possibly 
secondary to an inhibition of CETP. However, it should be 
emphasized that it is not known whether the HDL–C eleva-
tion associated with alcohol consumption is cardio-protective.
Smoking cessation 
Smoking reduces the concentration of HDL-C and smoking 
cessation is associated with an up to 10% increase in HDL-C 
level. The mechanism by which smoking reduces the level of 
HDL–C is not known. 
Pharmacological management 
Levels of HDL–C are increased by treatment with several 
classes of currently available lipid-modifying agents. These in-
clude ﬁbrates, statins, and (especially) niacin, with evidence 
accumulating that such increases do translate into a reduced 
risk of cardiovascular disease. 
Fibrates
The ability of fibrates to increase in concentration of HDL–C 
in patients with type 2 diabetes is rather modest, with increas-
es of only 2% to 3% reported in two large clinical trials [12,13]. 
But treatment with fibrates (including gemfibrozil, bezafibrate, 104
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and fenofibrate) is highly effective in reducing coronary risk in 
people with the combination of low HDL–C and elevated tri-
glyceride [14]. In contrast, people with normal levels of HDL–
C and triglyceride levels appear to derive little macro-vascular 
benefit from treatment with fibrates. These results have been 
observed in both diabetic and non-diabetic subjects. However, 
the cardiovascular benefits of fibrates in people with low HDL–
C and high triglyceride are largely unrelated to fibrate-induced 
changes in either HDL–C or triglyceride. This suggests that a 
dyslipidemia characterized by a low HDL–C and high triglyc-
eride identifies a group of people who derive substantial bene-
fit from treatment with a fibrate but that the benefit is by a 
mechanism other than by changes in lipid concentrations.
Statins
Statins raise the level of HDL–C by 3% to 15%. The increase is 
greatest in those in whom the baseline level of HDL–C is low 
[15]. Given that the level of HDL–C tends to be low in patients 
with type 2 diabetes, it might be expected that the HDL–C in-
crease induced by a statin would be greater in diabetics than in 
non-diabetics. The reality is the opposite, with evidence that 
the increase in level of HDL–C following treatment with a statin 
is much less in diabetic than in non-diabetic patients [15]. The 
explanation and the clinical implications of a reduced HDL–C 
response to statins in people with diabetes is not known.
  Statins have been reported to have an adverse effect on glu-
cose homeostasis, including a possible increase in develop-
ment of new onset diabetes [16]. The mechanism is not 
known. The cholesterol content of pancreatic beta islet cells 
does impact of insulin synthesis and secretion with evidence 
that an increase in cell cholesterol content decreases insulin 
secretion [17]. However, given that statin treatment will, if 
anything, decrease cell cholesterol levels, this is an unlikely ex-
planation for the observed increase in new onset diabetes in 
people treated with statins. It is possible that statins decrease 
insulin sensitivity in the liver or muscle, although there is no 
direct experimental evidence to support this. Thus, it is cur-
rently not known why statins impact adversely on glucose ho-
meostasis. However, given the strong evidence that statins 
markedly reduce cardiovascular risk patients with type 2 dia-
betes [18], the clinical impact of a small increase in new onset 
diabetes is probably very small. 
Niacin
Niacin increases HDL–C by up to 35% [19]. In addition, treat-
ment with niacin is associated with a change in the subpopula-
tion distribution of HDLs towards larger particles [20], a change 
predictive of both a slowing of coronary disease progression 
and a reduction in cardiovascular events. 
  The precise mechanism by which niacin increases the con-
centration of HDL-C is not known, although there is evidence 
that it delays the catabolism of HDL particles, possibly by de-
creasing activity of CETP. There is also evidence that niacin 
increases the synthesis of apoA-I.
  In addition to increasing the plasma concentration of HDL–
C and apoA-I, niacin has the capacity to modify HDLs in such 
a way that their function is enhanced. In one study HDLs were 
isolated from patients with type 2 diabetes and compared with 
HDLs isolated from healthy subjects [8]. Effects of the isolated 
HDLs on endothelium-dependent vasodilation and early en-
dothelial progenitor cell-mediated endothelial repair were 
measured. Whereas the HDLs from healthy subjects stimulat-
ed endothelial nitric oxide production, reduced endothelial 
oxidant stress and improved both endothelium-dependent va-
sodilation and early endothelial progenitor cell-mediated en-
dothelial repair, these beneficial endothelial effects of HDL 
were not observed in the HDLs isolated from diabetic patients. 
However, after the diabetic patients had been treated for 3 
months with niacin, the ability of the isolated HDLs to stimu-
late endothelial nitric oxide, to reduce superoxide production 
and to promote endothelial progenitor cell-mediated endothe-
lial repair were greatly improved [8]. 
  Niacin has also been reported both to enhance the anti-in-
flammatory effects of HDLs [21] and to inhibit vascular in-
flammation by a mechanism that appears to be unrelated to 
changes in plasma lipids [22].
  There is mounting evidence that treatment with niacin re-
duces cardiovascular events and promotes regression of ath-
erosclerosis [23] as revealed by imaging studies in human, 
with emerging evidence that the benefit is related (at least in 
part) to the magnitude of the increase in HDL–C. 
  If niacin is so effective, why is it not more widely used? The 
original, immediate release forms of niacin caused severe 
flushing that resulted in many people stopping the medication. 
And those who did take it were often unable to achieve the 
recommended therapeutic dose of 2 g per day. The flushing 
problem has been substantially reduced by the development of 
newer extended release formulations of niacin. Not only is the 
extended release form better tolerated but it may be taken as a 
single daily dose rather than in three divided doses as was the 105
HDL in patients with diabetes
Diabetes Metab J 2011;35:101-106 http://e-dmj.org
case with the immediate release form of the drug [24]. Flush-
ing is reduced even more when an extended release form of 
niacin is combined with the anti-flushing agent, laropiprant, 
allowing more patients to take the drug at its recommended 
dose of 2 g per day [25]. The mechanism by which niacin 
causes flushing is understood. It binds to a receptor in the skin 
that leads to the production of PGD2. PGD2 then binds to the 
DP1 receptor causing dilation of the blood vessels in the skin 
leading to flushing. Laropiprant blocks the DP1 receptor and 
thus inhibits the flushing caused by niacin
  Like statins, niacin is also known to have adverse effects on 
glucose homeostasis by decreasing insulin sensitivity and pos-
sibly worsening diabetic control. Whether the effects of niacin 
on glucose homeostasis are of clinical importance is uncertain 
but will be determined by the results of ongoing cardiovascu-
lar clinical outcome trials with niacin.
CONCLUSION
Many patients with type 2 diabetes have a low plasma concen-
tration of HDL–C that may contribute to an increased risk of 
developing cardiovascular disease. The observation that HDLs 
have beneficial effects on pancreatic beta cell function and 
glucose uptake by skeletal muscle, adds support to the propo-
sition that HDL-raising in people with type 2 diabetes may be 
anti-atherogenic as a consequence of both direct effects on the 
artery wall and also by improving diabetic control. It will be of 
great interest to see whether studies with HDL raising agents 
such as CETP inhibitors currently under investigation in clini-
cal trials have beneficial effects on diabetic control. 
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